Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity

Clinical Endocrinology

Volumn 69, Issue 3, 2008, Pages 452-461

  Krag, Morten B ^a   Nielsen, Søren ^a   Guo, Zengkui ^b   Pedersen, Steen B ^a   Schmitz, Ole ^c   Christiansen, Jens S ^a   Jørgensen, Jens O L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b MAYO CLINIC   (United States)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; FATTY ACID; GROWTH HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GROWTH HORMONE DEFICIENCY; HUMAN; HUMAN TISSUE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID OXIDATION; LIPOLYSIS; MALE; MUSCLE BIOPSY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPOLYSIS; MALE; MIDDLE AGED; PLACEBOS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 49649108052     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03231.x     Document Type: Article

References (51)

1. Moller, N., Butler, P.C., Antsiferov, M.A. Alberti, K.G. (1989) Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia, 32, 105 110.
2. Jessen, N., Djurhuus, C.B., Jorgensen, J.O., Jensen, L.S., Moller, N., Lund, S. Schmitz, O. (2005) Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. American Journal of Physiology. Endocrinology and Metabolism, 288, E194 E199.
3. Moller, N., Schmitz, O., Jorgensen, J.O., Astrup, J., Bak, J.F., Christensen, S.E., Alberti, K.G. Weeke, J. (1992) Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. Journal of Clinical Endocrinology and Metabolism, 74, 1012 1019.
4. Mestron, A., Webb, S.M., Astorga, R., Benito, P., Catala, M., Gaztambide, S., Gomez, J.M., Halperin, I., Lucas-Morante, T., Moreno, B., Obiols, G., Pablos, P.D., Paramo, C., Pico, A., Torres, E., Varela, C., Vazquez, J.A., Zamora, J., Albareda, M. Gilabert, M. (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology, 151, 439 446.
5. Svensson, J., Fowelin, J., Landin, K., Bengtsson, B.A. Johansson, J.O. (2002) Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 87, 2121 2127.
6. Jorgensen, J.O., Pedersen, S.A., Thuesen, L., Jorgensen, J., Ingemann-Hansen, T., Skakkebaek, N.E. Christiansen, J.S. (1989) Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet, 1, 1221 1225.
7. Nielsen, S., Moller, N., Christiansen, J.S. Jorgensen, J.O. (2001) Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes, 50, 2301 2308.
8. Reaven, G.M., Hollenbeck, C., Jeng, C.Y., Wu, M.S. Chen, Y.D. (1988) Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes, 37, 1020 1024.
9. Boden, G., Chen, X., Ruiz, J., White, J.V. Rossetti, L. (1994) Mechanisms of fatty acid-induced inhibition of glucose uptake. Journal of Clinical Investigation, 93, 2438 2446.
10. Shulman, G.I. (2000) Cellular mechanisms of insulin resistance. Journal of Clinical Investigation, 106, 171 176.
11. Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L.J. DeFronzo, R.A. (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care, 24, 710 719.
12. Shulman, A.I. Mangelsdorf, D.J. (2005) Retinoid X receptor heterodimers in the metabolic syndrome. New England Journal of Medicine, 353, 604 615.
13. Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L.J. DeFronzo, R.A. (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism, 87, 2784 2791.
14. Rasouli, N., Raue, U., Miles, L.M., Lu, T., Di Gregorio, G.B., Elbein, S.C. Kern, P.A. (2005) Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. American Journal of Physiology. Endocrinology and Metabolism, 288, E930 E934.
15. DeFronzo, R.A., Tobin, J.D. Andres, R. (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology, 237, E214 E223.
16. Orskov, H., Thomsen, H.G. Yde, H. (1968) Wick chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature, 219, 193 195.
17. Frystyk, J., Dinesen, B. Orskov, H. (1995) Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regulation, 5, 169 176.
18. Krassas, G.E., Pontikides, N., Kaltsas, T., Dumas, A., Frystyk, J., Chen, J.W. Flyvbjerg, A. (2003) Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. Journal of Clinical Endocrinology and Metabolism, 88, 132 135.
19. Hoybye, C., Bruun, J.M., Richelsen, B., Flyvbjerg, A. Frystyk, J. (2004) Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment. European Journal of Endocrinology, 151, 457 461.
20. Espelund, U., Hansen, T.K., Orskov, H. Frystyk, J. (2003) Assessment of ghrelin. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 109, 140 145.
21. Harrison, J., Hodson, A.W., Skillen, A.W., Stappenbeck, R., Agius, L. Alberti, K.G. (1988) Blood glucose, lactate, pyruvate, glycerol, 3-hydroxybutyrate and acetoacetate measurements in man using a centrifugal analyser with a fluorimetric attachment. Journal of Clinical Chemistry and Clinical Biochemistry, 26, 141 146.
22. Eriksson, B.M. Persson, B.A. (1982) Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection. Journal of Chromatography, 228, 143 154.
23. Miles, J.M., Ellman, M.G., McClean, K.L. Jensen, M.D. (1987) Validation of a new method for determination of free fatty acid turnover. American Journal of Physiology, 252, E431 E438.
24. Jensen, M.D., Rogers, P.J., Ellman, M.G. Miles, J.M. (1988) Choice of infusion-sampling mode for tracer studies of free fatty acid metabolism. American Journal of Physiology, 254, E562 E565.
25. Folch, J., Lees, M. Sloane Stanley, G.H. (1957) A simple method for the isolation and purification of total lipids from animal tissues. Journal of Biological Chemistry, 226, 497 509.
26. Humphreys, S.M., Fisher, R.M. Frayn, K.N. (1990) Micro-method for measurement of sub-nanomole amounts of triacylglycerol. Annals of Clinical Biochemistry, 27, 597 598.
27. Hietanen, E. Greenwood, M.R. (1977) A comparison of lipoprotein lipase activity and adipocyte differentiation in growing male rats. Journal of Lipid Research, 18, 480 490.
28. Frayn, K.N. (1983) Calculation of substrate oxidation rates in vivo from gaseous exchange. Journal of Applied Physiology, 55, 628 634.
29. Semple, R.K., Chatterjee, V.K. O'Rahilly, S. (2006) PPAR gamma and human metabolic disease. Journal of Clinical Investigation, 116, 581 589.
30. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M. Kliewer, S.A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). Journal of Biological Chemistry, 270, 12953 12956.
31. Petersen, K.F. Shulman, G.I. (2006) Etiology of insulin resistance. American Journal of Medicine, 119, S10 S16.
32. Roden, M., Price, T.B., Perseghin, G., Petersen, K.F., Rothman, D.L., Cline, G.W. Shulman, G.I. (1996) Mechanism of free fatty acid-induced insulin resistance in humans. Journal of Clinical Investigation, 97, 2859 2865.
33. Dresner, A., Laurent, D., Marcucci, M., Griffin, M.E., Dufour, S., Cline, G.W., Slezak, L.A., Andersen, D.K., Hundal, R.S., Rothman, D.L., Petersen, K.F. Shulman, G.I. (1999) Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. Journal of Clinical Investigation, 103, 253 259.
34. Boden, G., Cheung, P., Mozzoli, M. Fried, S.K. (2003) Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism, 52, 753 759.
35. Bajaj, M., Suraamornkul, S., Hardies, L.J., Pratipanawatr, T. DeFronzo, R.A. (2004) Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. International Journal of Obesity and Related Metabolic Disorders, 28, 783 789.
36. Petersen, K.F., Krssak, M., Inzucchi, S., Cline, G.W., Dufour, S. Shulman, G.I. (2000) Mechanism of troglitazone action in type 2 diabetes. Diabetes, 49, 827 831.
37. Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R., Ohannesian, J.P., Marco, C.C., McKee, L.J., Bauer, T.L. Caro, J.F. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine, 334, 292 295.
38. Bogacka, I., Xie, H., Bray, G.A. Smith, S.R. (2004) The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care, 27, 1660 1667.
39. Richelsen, B., Pedersen, S.B., Kristensen, K., Borglum, J.D., Norrelund, H., Christiansen, J.S. Jørgensen, J. (2000) Regulation of lipoprotein lipase and hormone-sensitive lipase activity and gene expression in adipose and muscle tissue by growth hormone treatment during weight loss in obese patients. Metabolism, 49, 906 911.
40. Oscarsson, J., Ottosson, M. Eden, S. (1999) Effects of growth hormone on lipoprotein lipase and hepatic lipase. Journal of Endocrinological Investigation, 22, 2 9.
41. Racette, S.B., Davis, A.O., McGill, J.B. Klein, S. (2002) Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus. Metabolism, 51, 169 174.
42. Mayerson, A.B., Hundal, R.S., Dufour, S., LeBon, V., Befroy, D., Cline, G.W., Enocksson, S., Inzucchi, S.E., Shulman, G.I. Petersen, K.F. (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes, 51, 797 802.
43. Jorgensen, J.O., Moller, J., Alberti, K.G., Schmitz, O., Christiansen, J.S.O., Rskov, H. Moller, N. (1993) Marked effects of sustained low growth hormone (GH) levels on day-to-day fuel metabolism: studies in GH-deficient patients and healthy untreated subjects. Journal of Clinical Endocrinology and Metabolism, 77, 1589 1596.
44. Maison, P., Griffin, S., Nicoue-Beglah, M., Haddad, N., Balkau, B. Chanson, P. (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. Journal of Clinical Endocrinology and Metabolism, 89, 2192 2199.
45. Moller, N., Moller, J., Jorgensen, J.O., Ovesen, P., Schmitz, O., Alberti, K.G. Christiansen, J.S. (1993) Impact of 2 weeks high dose growth hormone treatment on basal and insulin stimulated substrate metabolism in humans. Clinical Endocrinology, 39, 577 581.
46. Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., Nakamura, T., Shimomura, I. Matsuzawa, Y. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 50, 2094 2099.
47. Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R.E. Tataranni, P.A. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism, 86, 1930 1935.
48. Ouchi, N., Kihara, S., Arita, Y., Okamoto, Y., Maeda, K., Kuriyama, H., Hotta, K., Nishida, M., Takahashi, M., Muraguchi, M., Ohmoto, Y., Nakamura, T., Yamashita, S., Funahashi, T. Matsuzawa, Y. (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation, 102, 1296 1301.
49. Svensson, J., Herlitz, H., Lundberg, P.A. Johannsson, G. (2005) Adiponectin, leptin, and erythrocyte sodium/lithium countertransport activity, but not resistin, are related to glucose metabolism in growth hormone-deficient adults. Journal of Clinical Endocrinology and Metabolism, 90, 2290 2296.
50. Hana, V., Silha, J.V., Justova, V., Lacinova, Z., Stepan, J.J. Murphy, L.J. (2004) The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clinical Endocrinology, 60, 442 450.
51. Silha, J.V., Krsek, M., Hana, V., Marek, J., Jezkova, J., Weiss, V. Murphy, L.J. (2003) Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clinical Endocrinology, 58, 736 742.